• Earlier in June 2026, Roche announced an exclusive worldwide licensing and collaboration agreement with Nurix Therapeutics to co-develop and commercialize bexobrutideg (NX-5948), anchored by a US$700 million upfront payment and potential total deal value of up to US$2.30 billion.
• The agreement pairs Nurix’s BTK degrader platform with Roche’s global development and commercialization infrastructure across oncology, immunology and neurology, potentially reshaping bexobrutideg’s path from a single-asset cancer program into a multi-indication franchise candidate.
• We’ll examine how this extensive Roche partnership around bexobrutideg, including shared development costs and U.S. profit split, influences Nurix’s investment narrative.

Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

What Is Nurix Therapeutics' Investment Narrative?

To own Nurix today, you essentially have to believe that targeted protein degradation, and bexobrutideg in particular, can justify a premium valuation even while the company is loss making and expected to stay that way for several years. The fresh Phase 1a/1b CLL/SLL data and the Roche tie-up both speak directly to that belief: the drug now has early clinical support and a global partner willing to put US$700 million upfront on the table. Near term, the most important catalysts shift toward regulatory progress and execution on the pivotal DAYBreak trial, plus clarity on antitrust clearance and closing of the Roche deal. The biggest risks now look more concentrated in clinical and regulatory outcomes for bexobrutideg, as well as Nurix’s ability to fund its 40% share of development without further heavy dilution, rather than purely on financing risk.

However, one concentration risk around bexobrutideg is worth understanding in more detail. The analysis detailed in our Nurix Therapeutics valuation report hints at an inflated share price compared to its estimated value.

Exploring Other Perspectives

With one Simply Wall St Community fair value at US$31.44, some private investors see upside, yet the Roche collaboration and bexobrutideg trial dependence remind you how much hinges on a single program’s execution.

Explore another fair value estimate on Nurix Therapeutics - why the stock might be worth just $31.44!

The Verdict Is Yours

Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Nurix Therapeutics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision.
• Our free Nurix Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Nurix Therapeutics' overall financial health at a glance.

Ready To Venture Into Other Investment Styles?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• We've uncovered the 8 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 14 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.